[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Infection generates natural immunity", "description": "Which seems good and long lasting and cheap, lots of evidence below.\n\nhttps://www.thelancet.com/journals/laninf/article/PIIS1473-3099(21)00676-9/fulltext\n\nBiological studies\n\nDan et al (2021) Science, Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.\n\nhttps://www.science.org/doi/abs/10.1126/science.abf4063\n\n95% of participants tested retained immune memory at about 6 months after having COVID-19\n\nMore than 90% of participants had CD4+ T-cell memory at 1 month,\n\nand 6\u20138 months after having COVID-19\n\n\nWang et al (2021) Science, Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants\n\nhttps://www.science.org/doi/abs/10.1126/science.abh1766\n\nPrevious SARS-CoV-2 infection,\n\nwith an ancestral variant produce antibodies that cross-neutralise emerging variants of concern with high potency\n\nEpidemiological studies\n\nHansen et al (2021) Lancet, Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study\n\nhttps://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(21)00575-4.pdf\n\n\nPeople who had had COVID-19 previously were around 80\u00b75% protected against reinfection\n\n\nPilz et al (2021) European Journal of Clinical Investigation, SARS-CoV-2 re-infection risk in Austria\n\nhttps://onlinelibrary.wiley.com/doi/full/10.1111/eci.13520\n\nSheehan et al (2021) Clinical Infectious Diseases, Reinfection rates among patients who previously tested positive for COVID-19: a retrospective cohort study\n\nhttps://academic.oup.com/cid/article/73/10/1882/6170939?login=true\n\nShrestha et al (2021) Preprint, Necessity of COVID-19 vaccination in previously infected individuals\n\nhttps://www.medrxiv.org/content/10.1101/2021.06.01.21258176v3\n\nRetrospective cohort study in the USA, \n\nPeople who had had COVID-19 previously were 100% protected against reinfection\n\n\nGazit et al (2021) Preprint, Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections\n\nhttps://www.medrxiv.org/content/10.1101/2021.08.24.21262415.abstract\n\nKojima et al (2021) Preprint, Incidence of severe acute respiratory syndrome coronavirus-2 infection among previously infected or vaccinated employees\n\nhttps://www.medrxiv.org/content/10.1101/2021.07.03.21259976v2\n\nLaboratory staff routinely screened for SARS-CoV-2, \n\npeople who had had COVID-19 previously were 100% protected against reinfection\n\nClinical studies\n\nhttps://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(21)00675-9.pdf\n\nLarge, multicentre, prospective cohort study\n\nPrevious COVID-19 diagnosis,\n\n84% decreased risk of infection\n\nLetizia et al (2021) Lancet, Respiratory Medicine, SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study\n\nhttps://www.thelancet.com/pdfs/journals/lanres/PIIS2213-2600(21)00158-2.pdf\n\nProspective cohort of US Marines, \n\nseropositive young adults were 82% protected against reinfection\n\n\nAdnan et al (2021) Clinical Infectious Diseases, Reinfection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients Undergoing Serial Laboratory Testing\n\nhttps://academic.oup.com/cid/article/74/2/294/6251701?login=false\n\nN = 9,119, serial tests\n\nReinfection rates, 0.7%\n\nSo\n\nRisk of repeat SARS-CoV-2 infection decreased by 80\u00b75\u2013100% among those who had had COVID-19\n\nProtection from reinfection is strong and persists for more than 10 months of follow-up, (Hansen et al 2021 Lancet)\n\nTurner, et al Nature, SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans\n\nhttps://www.nature.com/articles/s41586-021-03647-4?amp%3Bcode=7bafb609-23c2-4665-804b\n\nMadhuumita et al, Plos One, T cell response to SARS-CoV-2 infection in humans: A systematic review\n\nhttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0245532\n\nSARS-CoV-2 infection induces specific and durable T-cell immunity, \n\nNina et al, (2020) Nature, SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls\n\nhttps://www.nature.com/articles/s41586-020-2550-z?flip=true\n\nMemory B-cell response to SARS-CoV-2 evolves between 1\u00b73 and 6\u00b72 months after infection, which is consistent with longer-term protection\n\nSome people who have recovered from COVID-19 might not benefit from COVID-19 vaccination\nhttps://www.medrxiv.org/content/10.1101/2021.04.20.21255670v1\n\n\nOne study found that previous COVID-19 was associated with increased adverse events following vaccination with Pfizer \n\nhttps://www.journalofinfection.com/article/S0163-4453(21)00277-2/fulltext\n\nIn Switzerland, proof of recovered infection, in the past 12 months are considered equally protected as fully vaccinated, \n\nhttps://www.schengenvisainfo.com/news/switzerland-plans-to-extend-covid-certificate-requirement-until-mid-november/", "link": "https://www.youtube.com/watch?v=L_CvfiJ3QRQ", "date_published": "2022-02-14 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]